Antimicrobial susceptibility of ESKAPE pathogens in the SS. Antonio e Biagio e Cesare Arrigo Hospital’s catchment area: December 2021 - July 2022

Background and Aims: this report describes the minimum inhibitory concentration distributions of the main drugs used against ESKAPE pathogens infection, recovered from patients treated between December 2021 and July 2022 at SS. Antonio e Biagio e Cesare Arrigo Hospital. Materials and Methods: data were extracted by a new Laboratory Information System implemented in mid-November 2021. Results: after exclusion of colonization: i) 56% of Enterococcus faecium was susceptible to teicoplanin and vancomycin; ii) 74% of Staphylococcus aureus was susceptible to methicillin; iii) 55.3% of Klebsiella pneumoniae was susceptible to cefotaxime, ceftazidime and cefepime and 93.2% of KPC was susceptible to ceftazidime/avibactam; iv) no Acinetobacter baumannii strains were resistant to colistin; v) 88.9% of Pseudomonas aeruginosa was susceptible to ceftolozane/tazobactam and 92.2% to ceftazidime/avibactam; vi) among Enterobacter species, 84.6% was susceptible to cefepime and 87.1% to ciprofloxacin. Conclusions: periodic reporting of local antibiotic resistance is an adjunctive tool to help the choice of antimicrobial therapy.